Drug Watch

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes.

Axsome Therapeutics advances AXS-05 for Alzheimer disease agitation, showing significant improvement in clinical trials and addressing critical patient needs.

Check out the pipeline updates from October!

Cingulate's CTx-1301 shows promising phase 3 results for ADHD, offering effective once-daily dosing and potential FDA approval by 2026.

New analysis reveals Ingrezza's 40 mg dose significantly improves tardive dyskinesia symptoms, showcasing long-term efficacy and safety in patients.

Uzedy, a once-monthly extended release long-acting injectable, is now FDA approved for bipolar I disorder.

Cingulate's CTx-1301, a novel ADHD treatment, gains FDA review, promising rapid relief and sustained efficacy for patients.

Data presented at the ECNP Conference showed CT-155 has promise in reducing negative symptoms of schizophrenia.

Esketamine nasal spray shows significant improvements in treatment-resistant depression, with effective dose management and minimal adverse effects in recent studies.

New research highlights lumateperone's effectiveness as an adjunctive treatment for major depressive disorder, improving depressive symptoms and sexual function.

Researchers unveil a groundbreaking nasal spray using lithium-loaded gold nanoparticles, targeting brain diseases with reduced adverse effects.

Alto Neuroscience's ALTO-101 gains FDA fast track designation, promising a novel treatment for cognitive impairment in schizophrenia.

Bristol Myers Squibb's BMS-986446 receives FDA Fast Track Designation, aiming to transform early Alzheimer disease treatment by targeting tau pathology.

Lipocine Inc. advances LPCN 1154, an oral treatment for postpartum depression, aiming for rapid relief and improved patient access by 2026.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

New phase 3 data highlights seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting primary end points. Andrew J. Cutler, MD, shares his thoughts.

INmune Bio reveals phase 2 trial results for XPro1595, a novel treatment targeting neuroinflammation in early Alzheimer disease.

Anebulo Pharmaceuticals initiates a phase 1 trial for selonabant, targeting acute cannabis toxicity in children with promising IV treatment potential.

A new study reveals tasimelteon (Hetlioz) significantly improves sleep onset in chronic insomnia patients.

Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.

A phase 2 study reveals osavampator significantly reduces depression severity in adults with major depressive disorder, showing promise for treatment-resistant cases.

New analysis reveals Ingrezza achieves rapid symptomatic remission in tardive dyskinesia, enhancing patient quality of life and reducing disease burden.